Moderna's COVID-19 vaccine candidate moves into late-stage trial
HEALTH

Moderna's COVID-19 vaccine candidate moves into late-stage trial

News Service Reuters

Moderna Inc said on Monday it has started a U.S. government-backed late-stage trial evaluating its COVID-19 vaccine candidate, mRNA-1273, in about 30,000 adults who do not have the respiratory illness caused by the new coronavirus.

The main goal of the study will be prevention of the symptomatic COVID-19 disease, the company said.

+

We use cookies limited for the aims specified in the data policy and in accordance with the legislation. For details please see our data policy.